Loteprednol etabonate/tobramycin

Drug Profile

Loteprednol etabonate/tobramycin

Alternative Names: LE-T; LE-Tobramycin; Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension; Tobramycin/loteprednol etabonate; Zylet

Latest Information Update: 22 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmos Corporation
  • Class Aminoglycosides; Androstadienes; Eye disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 27 Jan 2005 First global launch of loteprednol etabonate/tobramycin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top